After seventeen years of suffering extensive neurological damage from relapsing remitting multiple sclerosis (RRMS), I ditched my FDA approved therapy and took a chance with an off-label drug called daclizumab. In seven years of treatment, I’ve gotten only one new lesion. Daclizumab is currently being tested for safety and efficacy by the National Institutes of Health (NIH).
I am one of the lucky few being treated with the drug, which now goes by the name of DAC HYP. I am hopeful that in a few years, DAC HYP will become an approved therapy, and more people will have the chance to see the progress of their disease dramatically stalled. DAC HYP is not a cure. I still have to deal with all the symptoms caused by the neurological damage I’ve accrued. I also have to deal with the one side effect of skin rashes. This blog charts the course of my trials during the clinical trial.
For the official story on the drug trial, try http://www.clinicaltrials.gov/ct2/show/NCT01143441?term=10-n-0125&rank=1